EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 35 / Numéro 12 (Décembre 2019) Med Sci (Paris), 35 12 (2019) 1062-1065 Références
Open Access
Numéro
Med Sci (Paris)
Volume 35, Numéro 12, Décembre 2019
Anticorps monoclonaux en thérapeutique
Page(s) 1062 - 1065
Section Les anticorps armés
DOI https://doi.org/10.1051/medsci/2019206
Publié en ligne 6 janvier 2020
  1. Mathé G, Loc Tran Ba, Bernard J , Effet sur la leucémie 1210 de la souris d’une combinaison par diazotation d’améthopterine et de gammaglobulines de hamsters porteurs de cette leucémie par hétérogreffe. CR Hebd Seances Acad Sci. 1958;246:1626–1628. [Google Scholar]
  2. Srivastava SC, Buraggi GL , NATO Advanced study institute on radiolabeled monoclonal antibodies for imaging and therapy–potential, problems, and prospects. Int J Biol Markers. 1987;2:43–48. [CrossRef] [PubMed] [Google Scholar]
  3. Robbins RJ, Schlumberger MJ , The evolving role of 131I for the treatment of differentiated thyroid carcinoma. J Nucl Med. 2005;46(suppl 1):S28–S37. [Google Scholar]
  4. Grünwald F, Ezziddin S , 131I-metaiodobenzylguanidine therapy of neuroblastoma and other neuroendocrine tumors. Semin Nucl Med. 2010;40:153–163. [CrossRef] [PubMed] [Google Scholar]
  5. Goldenberg DM , Current status of cancer imaging with radiolabeled antibodies. J Cancer Res Clin Oncol. 1987;113:203–208. [CrossRef] [PubMed] [Google Scholar]
  6. Mach JP, Carrel S, Forni M, et al. Tumor localization of radiolabeled antibodies against carcinoembryonic antigen in patients with carcinoma: a critical evaluation. N Engl J Med. 1980;303:5–10. [Google Scholar]
  7. Larson SM, Carrasquillo JA, Cheung N-KV, et al. Radioimmunotherapy of human tumours. Nat Rev Cancer. 2015;15:347–360. [Google Scholar]
  8. Goldsmith SJ , Radioimmunotherapy of lymphoma: Bexxar and Zevalin®. Semin Nucl Med. 2010;40:122–135. [CrossRef] [PubMed] [Google Scholar]
  9. Vallabhajosula S, Nikolopoulou A, Jhanwar YS, et al. Radioimmunotherapy of metastatic prostate cancer with 177Lu-DOTAhuJ591 anti-prostate specific membrane antigen specific monoclonal antibody. Curr Radiopharm. 2016;9:44–53. [CrossRef] [PubMed] [Google Scholar]
  10. Brans B, Bodei L, Giammarile F, et al. Clinical radionuclide therapy dosimetry: the quest for the Holy Gray. Eur J Nucl Med Mol Imaging. 2007;34:772–786. [PubMed] [Google Scholar]
  11. Strosberg J, Krenning E , 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:1391–1392. [Google Scholar]
  12. von Eyben FE, Roviello G, Kiljunen T, et al. Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review. Eur J Nucl Med Mol Imaging. 2018;45:496–508. [PubMed] [Google Scholar]
  13. Loktev A, Lindner T, Mier W, et al. A Tumor-imaging method targeting cancer-associated fibroblasts. J Nucl Med. 2018;59:1423–1429. [CrossRef] [PubMed] [Google Scholar]
  14. Wissing MD, van Leeuwen FWB, van der Pluijm G, et al. Radium-223 chloride: extending life in prostate cancer patients by treating bone metastases. Clin Cancer Res. 2013;19:5822–5827. [CrossRef] [PubMed] [Google Scholar]
  15. Kratochwil C, Bruchertseifer F, Giesel FL, et al. 225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer. J Nucl Med. 2016;57:1941–1944. [CrossRef] [PubMed] [Google Scholar]
  16. Jurcic JG , Clinical studies with Bismuth-213 and Actinium-225 for hematologic malignancies. Curr Radiopharm. 2018;11:192–199. [CrossRef] [PubMed] [Google Scholar]
  17. Meredith R, Torgue J, Shen S, et al. Dose escalation and dosimetry of first-in-human α-radioimmunotherapy with 212Pb-TCMC-trastuzumab. J Nucl Med. 2014;55:1636–1642. [CrossRef] [PubMed] [Google Scholar]
  18. Sgouros G , Alpha-particles for targeted therapy. Adv Drug Deliv Rev. 2008;60:1402–1406. [CrossRef] [PubMed] [Google Scholar]
  19. Batra SK, Jain M, Wittel UA, et al. Pharmacokinetics and biodistribution of genetically engineered antibodies. Curr Opin Biotechnol. 2002;13:603–608. [Google Scholar]
  20. Chatal JF, Campion L, Kraeber-Bodéré F, et al. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol. 2006;24:170511. [Google Scholar]
  21. Altai M, Membreno R, Cook B, et al. Pretargeted Imaging and therapy. J Nucl Med. 2017;58:1553–1559. [CrossRef] [PubMed] [Google Scholar]
  22. Joubert N, et al. ADC : le grand retour des médicaments couplés aux anticorps. Med Sci (Paris). 2019;35:1034–1042. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  23. Ménager J, Gorin JB, Fichou N , Radio-immunothérapie alpha : principes et intérêts en immunité antitumorale. Med Sci (Paris). 2016;32:362–369. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  24. Mortier L, et al. Une révolution en oncologie, bilan de l’efficacité. Med Sci (Paris). 2019;35:937–945. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  25. Morschhauser F, Radford J, Van Hoof A, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol. 2008;26:5156–5164. [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.